Metabolic Homeostasis: HDACs Take Center Stage

blogEntryThumbnail

Synthetic PPARg ligands (such as TZDs) are currently the most powerful insulin sensitizers in the treatment of type 2 diabetes in clinics. Of two TZD-based medicines (rosiglitazone and pioglitazone), rosiglitazone was withdrawn in the European market last year and will be removed from pharmacy stores in US by this November. The rosiglitazone-associated heart failure is responsible for the end of its market performance in Europe and US. A potential side effect in bladder cancer is another threat to the value of TZD-based medicines for type 2 diabetes. Do scientist have any new leads towards drug targets/candidates to replace TZD-based medicines?
Read More...

Comments

New Scientific Skills for New Types of Scientific Communication

blogEntryThumbnail

After almost 10 years in training, I recently started my new lab: an exhilarating and scary prospect. It was now all up to me. Was I ready? Did I have the skills to compete as a scientist in an era of expensive science, funding cuts, and grant paylines in the single digits? Sure, I was well-trained as a chemist and molecular biologist to generate hypotheses and design experiments, run western blots, PCRs, and even the occasional animal physiology. But as I transitioned from my post-doctoral studies to my new faculty position, how many of these skills would prepare me for faculty-dom? To my surprise, I found myself woefully unequipped with one specific skill set: the skills needed to successfully communicate in a new, scientific digital-age. Read More...

Comments